.... There are 5 known somatostatin receptor subtypes (SSTRs), 2 of which, i.e. SSTR2 and SSTR5, are expressed by a majority of somatotroph adenomas. The currently available SRLs, i.e. octreotide and lanreotide, primarily bind to SSTR2. Pasireotide (SOM230) is a new multireceptor-targeted SRL which has a broader...

... combined therapy might be partially explained by an increase of about 20% in serum levels of pegvisomant [ 60 ]. Biochemical hepatic anomalies were quite frequent (although always transient) with this combination [ 61,62 ]. The availability of new SAs such pasireotide may also be helpful...

... the anti-tumor effects of SST analogs in carcinoids. Additionally, ERK1/2 phosphorylating agents have been shown to suppress biomarker expression in carcinoids. Thus, Raf-1/MEK/ERK1/2 pathway activating drugs may be synergistic with SST analogs such as pasireotide (SOM230), which may be more effective than...

... octreotide acts mainly via the sst 2 receptor, the novel pan-somatostatin analog pasireotide exhibits particular high affinity for the sst 5 receptor. To determine whether a patient is a candidate for octreotide or pasireotide therapy, it is important to evaluate the somatostatin receptor status. However, so...

...Alberto M. Pedroncelli Cushing’s disease is Cushing’s syndrome caused by an adrenocorticotropic hormone-secreting pituitary adenoma and, in the absence of adequate treatment, can be fatal. Cushing’s disease represents an unmet medical need, with no approved medical therapies. Pasireotide is a novel...